Table 3.
TMS-EMG metrics in rare epilepsies.
| Subjects | Findings (relative to control); Comments | ||||
|---|---|---|---|---|---|
| MT | SICI | ICF | LICI | CSP | |
| PME | -/↑ (rMT unchanged or increased; aMT increased in ULD and LBD) | ↓ | ↓ (LBD only) | ↓ (- in ULD) | - |
| DS | - | ↓ | - | - | |
| SSADHD | ↑/- (unchanged after taurine treatment) | -/↑ (increased after taurine treatment) | ↓/-(unchanged after taurine treatment) | ↑/- | ↓ |
| LGS | ↑ | ↑ | ↑ | ↑ | |
MT, motor threshold; SICI, short-interval intracortical inhibition; ICF, intracortical facilitation; LICI, long-interval intracortical facilitation; CSP, cortical silent period; PME, primary myoclonus epilepsies; LBD, Lafora body disease; ULD, Unverricht-Lundborg disease; DS, Dravet syndrome; SSADHD, succinic semialdehyde dehydrogenase deficiency; LGS, Lennox–Gastaut Syndrome; ↑, increase; ↓, decrease; -: no change; blank cells, not tested; results for cohort 1, results for cohort 2; /: conflicting results.